ASTH vs WELL vs VTR vs ALHC

For growth investors, Astrana Health, Inc.

(ASTH) is the stronger pick with 56. 4% revenue growth year-over-year, versus 18. 5% for Ventas, Inc. (VTR). Astrana Health, Inc. (ASTH) offers the better valuation at 78. 4x trailing P/E (29. 1x forward), making it the more compelling value choice. Analysts rate Astrana Health, Inc. (ASTH) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Astrana Health, Inc.

(ASTH) is the cheapest at 78. 4x versus Ventas, Inc. at 160. 3x. On forward P/E, Astrana Health, Inc. is actually cheaper at 29. 1x.

Over the past 5 years, Welltower Inc.

(WELL) delivered a total return of +202. 3%, compared to -22. 7% for Alignment Healthcare, Inc. (ALHC). Over 10 years, the gap is even starker: ASTH returned +614. 5% versus ALHC's +5. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ventas, Inc.

(VTR) is the lower-risk stock at 0. 01β versus Astrana Health, Inc. 's 1. 11β — meaning ASTH is approximately 11584% more volatile than VTR relative to the S&P 500. On balance sheet safety, Welltower Inc. (WELL) carries a lower debt/equity ratio of 49% versus 193% for Astrana Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Astrana Health, Inc.

(ASTH) is pulling ahead at 56. 4% versus 18. 5% for Ventas, Inc. (VTR). On earnings-per-share growth, the picture is similar: Ventas, Inc. grew EPS 184. 2% year-over-year, compared to -48. 9% for Astrana Health, Inc.. Over a 3-year CAGR, ASTH leads at 40. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Welltower Inc.

(WELL) is the more profitable company, earning 8. 8% net margin versus -0. 0% for Alignment Healthcare, Inc. — meaning it keeps 8. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VTR leads at 14. 2% versus 0. 4% for ALHC. At the gross margin level — before operating expenses — WELL leads at 39. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Astrana Health, Inc.

(ASTH) trades at 29. 1x forward P/E versus 140. 9x for Alignment Healthcare, Inc. — 111. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALHC: 36. 1% to $24. 83.

In this comparison, VTR (2.

1% yield), WELL (1. 3% yield), ASTH (0. 4% yield) pay a dividend. ALHC does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Ventas, Inc.

(VTR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 01), 2. 1% yield). Both have compounded well over 10 years (VTR: +65. 0%, ALHC: +5. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ASTH (Healthcare) and WELL (Real Estate) and VTR (Real Estate) and ALHC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

WELL, VTR pay a dividend while ASTH, ALHC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.